Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Sponsor: Allist Pharmaceuticals, Inc.
Summary
Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Official title: A Phase Ib/II ,Single Arm, Multi-Center, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of JAB-21822 in Advanced or Metastatic Non-small Cell Lung Cancer With a KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2022-08-17
Completion Date
2026-02
Last Updated
2025-04-04
Healthy Volunteers
No
Conditions
Interventions
JAB 21822
Administered orally
Locations (21)
Research site08
Beijing, Beijing Municipality, China
Research site09
Beijing, Beijing Municipality, China
Research site021
Beijing, Beijing Municipality, China
Research site02
Beijing, Beijing Municipality, China
Research site01
Beijing, Beijing Municipality, China
Research site013
Beijing, Beijing Municipality, China
Research site010
Chongqing, Chongqing Municipality, China
Research site05
Xiamen, Fujian, China
Research site011
Shenzhen, Guangdong, China
Research site016
Nanning, Guangxi, China
Research site017
Shijiazhuang, Hebei, China
Research site018
Harbin, Heilongjiang, China
Research site04
Zhengzhou, Henan, China
Research site012
Changsha, Hunan, China
Research site015
Changchun, Jilin, China
Research site06
Shenyang, Liaoning, China
Research site07
Shenyang, Liaoning, China
Research site014
Hohhot, Neimenggu, China
Research site020
Xi’an, Shanxi, China
Research site03
Hubei, Wuhan, China
Research site019
Hangzhou, Zhejiang, China